Regeneron Pharmaceuticals Aktie
WKN: 881535 / ISIN: US75886F1075
|
29.04.2026 12:53:55
|
Cognizant Updates FY26 Guidance
(RTTNews) - Cognizant (CTSH) said its 2026 adjusted operating margin guidance is increased to 16.0% to 16.2%, year-over-year expansion of 20 to 40 basis points compared to prior guidance of 10 to 30 basis points of expansion. Constant currency revenue growth guidance is unchanged at 4.0% to 6.5%. Full-year 2026 adjusted EPS is expected to be in the range of $5.63 to $5.77, growth of 7% to 9%. The company expects second quarter revenue to be $5.45 to $5.52 billion, growth of 3.8% to 5.3%, or 3.2% to 4.7% in constant currency.
First quarter net income was $662 million compared to $663 million, prior year. EPS was $1.39, increased 3.7% year-over-year. Adjusted EPS was $1.40 increased 13.8%. Adjusted Operating Margin was 15.6%, increased 10 basis points year-over-year. Revenue was $5.4 billion, up 5.8% from last year, or 3.9% in constant currency.
In pre-market trading on NasdaqGS, Cognizant shares are down 4.75 percent to $52.50.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Regeneron Pharmaceuticals Inc.
Analysen zu Regeneron Pharmaceuticals Inc.
Aktien in diesem Artikel
| Regeneron Pharmaceuticals Inc. | 532,70 | 3,02% |
|